Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.06
- Piotroski Score 6.00
- Grade Sector Perform
- Symbol (PCRX)
- Company Pacira BioSciences, Inc.
- Price $17.71
- Changes Percentage (0.23%)
- Change $0.04
- Day Low $17.03
- Day High $18.22
- Year High $35.95
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/27/2025
- Fiscal Year End N/A
- Average Stock Price Target $35.00
- High Stock Price Target $63.00
- Low Stock Price Target $8.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $1.51
- Trailing P/E Ratio 18.92
- Forward P/E Ratio 18.92
- P/E Growth 18.92
- Net Income $41.96 M
Income Statement
Quarterly
Annual
Latest News of PCRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings
Despite Pacira BioSciences' disappointing returns over three years, a recent 14% share price increase offers hope. Profitability and revenue growth suggest potential for further gains. Insiders buying...
By Yahoo! Finance | 1 month ago -
Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History - Yahoo Finance
Pacira BioSciences, Inc. announced that its U.S. Patent No. 11,033,495 was deemed invalid by the U.S. District Court for the District of New Jersey....
By Yahoo! Finance | 2 months ago -
Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History
Pacira BioSciences will join a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 6. The event will be live-streamed on the company's website, with a replay available for two wee...
By Yahoo! Finance | 4 months ago
